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Classification Rule for 5-year 
Cardiovascular Diseases Risk 
using decision tree in Primary 
Care Chinese Patients with Type 2 
Diabetes Mellitus
Eric Yuk Fai Wan1, Daniel Yee Tak Fong2, Colman Siu Cheung Fung1, Esther Yee Tak Yu1, Weng 
Yee Chin1, Anca Ka Chun Chan1 & Cindy Lo Kuen Lam1
Cardiovascular disease(CVD) is the leading cause of mortality among patients with type 2 diabetes 
mellitus(T2DM), and a risk classification model for CVD among primary care diabetic patients is pivotal 
for risk-based interventions and patient information. This study developed a simple tool for a 5-year 
CVD risk prediction for primary care Chinese patients with T2DM. A retrospective cohort study was 
conducted on 137,935 primary care Chinese T2DM patients aged 18–79 years without history of CVD 
between 1 January 2010 and 31 December 2010. New events of CVD of the cohort over a median 
follow up of 5 years were extracted from the medical records. A classification rule of 5-year CVD risk 
was obtained from the derivation cohort and validated in the validation cohort. Significant risk factors 
included in decision tree were age, gender, smoking status, diagnosis duration, obesity, unsatisfactory 
control on haemoglobin A1c and cholesterol, albuminuria and stage of chronic kidney disease, which 
categorized patients into five 5-year CVD risk groups(<5%; 5–9%; 10–14%; 15–19% and ≥20%). Taking 
the group with the lowest CVD risk, the hazard ratios varied from 1.92(1.77,2.08) to 8.46(7.75,9.24). 
The present prediction model performed comparable discrimination and better calibration from the plot 
compared to other current existing models.
Diabetes Mellitus (DM) is a leading cause of global burden affecting 415 million people in the world and expected 
to increase to 642 million by 20401. The estimated health expending on diabetes continues to rise to US$673 
billion, accounting for 11.6% of global health expenditure1. The medical costs for diabetic patients with cardio-
vascular diseases (CVD) is at least two-fold higher than those without CVD2, and constitutes 70% of mortality3. 
Numerous studies have found that CVD events can be prevented or delayed with lifestyle modification or use of 
pharmacotherapy in diabetic patients4,5. An important step in preventing or delaying the incidence of CVD is 
to identify diabetic patients who are at high risk so that they can receive earlier or more intensive intervention.
Most guidelines recommend that risk-stratified interventions for the management of DM in primary care 
should be delivered based on predicted overall CVD risk profile rather than individual risk factors and predicted 
subtype of CVD risk such as stroke and coronary heart disease4,5. Patients classified as low risk may be monitored 
less frequently, whereas patients classified as high risk may be given a closer and more intensive monitoring and 
intervention. Several CVD risk models have been developed to estimate the risk for stratifying patients into 
specific risk categories, in order to facilitate clinicians in making medical decisions or determining the effects of 
an intervention. Most models usually include individual prognostic factors but ignore their interaction effects 
even though studies have shown interaction effects with age6,7, and gender8,9. Furthermore, most of models have 
been developed and evaluated on predominantly Caucasian populations which may not be applicable to Chinese 
populations. Chinese account for approximately 25% of the diabetic population worldwide1, and a multinational 
study from the World Health Organization showed an ethnic disparities in CVD prevalence among diabetic 
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population10,11. Hence, there is a need to derive a Chinese specific risk classification model that accounts for 
potential interaction effects for CVD incidence. The aim of this study was to develop a simple risk classification 
tool to fast determine the 5-year CVD risk for patients with Type 2 DM (T2DM) which could be readily imple-
mented into routine clinical use using readily available clinical data.
Results and Discussion
A total of 137,935 eligible Chinese patients, aged between 18 and 79 years, were diagnosed clinically with T2DM 
and managed in public primary care clinics and without past history of CVD or end stage renal disease. Random 
split of the dataset resulted in 91,956 and 45,979 subjects in the derivation and validation cohorts, respectively. 
During the median follow-up period of 5.0 years in both cohorts, the number of CVD events in the derivation 
and validation cohorts were 8,124 and 4,154, respectively. Table 1 shows the baseline characteristics between 
the two cohorts. In general, there were more females (53.3%) than males (46.7%); the mean age was 62.1 years 
(standard deviation (SD): 10.0 years); 11.2% were current smokers and the mean duration of T2DM was 7.0 years 
(SD: 6.2 years).
Figure 1 shows the variable importance of all potential predictors. Unsatisfactory control on BP and dia-
betic retinopathy were excluded from main analysis since they had negative importance scores. A survival tree 
Derivation Cohort (N = 91,956) Validation Cohort (N = 45,979) p-value
Socio-Demographics
Gender 0.966
 Female 53.3% (48,982) 53.3% (24,486)
 Male 46.7% (42,974) 46.7% (21,493)
Age,years 62.06 ± 9.98 (91,956) 61.95 ± 9.98 (45,979) 0.065
 <50 years 11.0% (10,146) 11.0% (5,050) 0.226
 50–64 years 47.2% (43,400) 47.7% (21,923)
 ≥65 years 41.8% (38,410) 41.3% (19,006)
Smoking Status 0.765
 Non-Smoker 88.8% (81,169) 88.8% (40,595)
 Smoker 11.2% (10,247) 11.2% (5,097)
Clinical Characteristics
Duration of T2DM, years 7.00 ± 6.23 (85,063) 7.02 ± 6.26 (42,529) 0.516
 <2 years 18.0% (15,307) 18.0% (7,656) 0.534
 2–5 years 25.1% (21,345) 24.8% (10,553)
 ≥5 years 56.9% (48,411) 57.2% (24,320)
Diabetic Retinopathy 0.870
 No 50.6% (46,554) 50.7% (23,299)
 Yes 49.4% (45,402) 49.3% (22,680)
Obesity 0.966
 No 31.6% (23,994) 31.6% (11,975)
 Yes 68.4% (51,957) 68.4% (25,946)
Unsatisfactory control on HbA1c
 No 80.4% (72,606) 80.1% (36,169) 0.205
 Yes 19.6% (17,691) 19.9% (8,976)
Unsatisfactory control on BP
 No 61.4% (56,299) 61.7% (28,251) 0.379
 Yes 38.6% (35,356) 38.3% (17,559)
Unsatisfactory control on cholesterol
 No 60.1% (52,781) 60.1% (26,386) 0.947
 Yes 39.9% (35,054) 39.9% (17,510)
Albuminuria l
 No 74.2% (48,422) 74.1% (24,207) 0.803
 Microalbuminuria 21.3% (13,930) 21.3% (6,962)
 Macroalbuminuria 4.5% (2,923) 4.6% (1,493)
Stage of chronic kidney disease
 Stage 1 73.1% (65,492) 73.2% (32,714) 0.892
 Stage 2 23.0% (20,646) 23.0% (10,298)
 Stage 3 or above 3.9% (3,461) 3.8% (1,704)
Table 1. Baseline characteristics of derivation and validation cohorts. HbA1c = Haemoglobin A1c; BP = Blood 
pressure; T2DM = Type 2 diabetes mellitus; Notes: *Significant difference at 0.05 level by chi-square test or 
independent t-test, as appropriate.
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model was fitted using the remaining potential predictors with positive importance scores including age, gen-
der, smoking status, diabetes duration, obesity, unsatisfactory control on HbA1c and cholesterol, albuminuria 
and estimated glomerular filtration rate (eGFR), and 38 terminal nodes/groups were obtained and shown in 
Supplementary Figure 1. The average absolute 5-year CVD risk among these groups varied from 1.73% to 39.6%, 
and hazard ratios (HR) by taking the group with the lowest CVD risk as reference level were between 1.8 and 28.9. 
After stratifying each terminal node/group into one of the five different severity risk groups (<5%; 5–9%; 10–14%; 
15–19% and ≥20%), a final simplified tree was constructed in Figure 2. Figure 3 showed the Kaplan-Meier curves 
for these five groups and showed significant difference between groups by log-rank test. Taking the group with 
the lowest CVD risk, the hazard ratios for other groups varied from 1.92 (1.77, 2.08) to 8.46 (7.75, 9.24) in Table 2. 
All pairwise comparisons were statistically significant, indicating the stratification of the CVD risk was effective 
and appropriate to separate the subjects.
The performance of the new model was compared with existing CVD risk models using the validation cohort 
and the results are shown in Table 3. In terms of predictive power, the Harrell’s C statistic for new model was 
0.677, which was similar with Swedish model (0.685) and was superior than the others and the difference also 
reached statistically significance. Supplementary Table 1 showed similar results using 10-fold cross validation. 
Meanwhile, the calibration power of the five different models on five different CVD risk groups was compared in 
Figure 4. The five predicted 5-year CVD risk groups were matched with the observed CVD risk for our model, 
indicating a good calibration. Swedish model slightly underestimated the observed 5-year CVD incidence rate in 
the predicted 15–20% risk group. Other models showed a poor calibration with either an underestimation or an 
overestimation on the actual CVD risk.
This study developed a simple risk stratification tool to quickly establish the CVD risk for patients with DM 
using clinical information extracted from a territory-wide patient dataset. Our developed model had comparable 
discriminatory and superior calibration power when compared to other developed CVD prediction models. The 
current findings also identified the importance of the presence of chronic kidney disease and albuminuria in 
predicting CVD risk amongst Chinese patients with DM.
This is the first study to use a decision tree analysis to identify and classify CVD risk in patients with T2DM. 
The main advantage of using a decision tree analysis is the ability to convert complicated risk equations into an 
organized flowchart, which can be easily navigated to identify the appropriate risk. This is important in clinical 
practice, where short consultation times can make more complex risk stratification tools less amenable to being 
used. A simple, practical and user-friendly approach can help promote clinicians to make more valid risk-based 
decisions on intervention. Furthermore, this tool can help to minimize the need for unnecessary measurements 
with a view to reduce the treatment burden and unnecessary use of health resources.
There were nine predictors in our developed model, which is lower than other existing models based on dia-
betic populations12–14. Furthermore, other models usually rely on a single sophisticated mathematical formula, 
which may not work if one of parameters is missing. In our developed model, it is still possible to estimate a risk 
level with missing data. For example, in a male, non-smoker, aged <65 years old, with eGFR ≥90 ml/min/1.73 m2 
and no albuminuria but missing lipid profile, this patient can be classified into either <5% or 5–9% risk group, 
which indicates the 5-year CVD risk should be less than 10%.
Regarding the accuracy of the risk prediction, our model demonstrated similar discrimination but better 
calibration power than other existing models. Calibration, which measures the agreement between observed 
Figure 1. Error rate and variable importance from the random survival tree analysis using the rfsrc function 
with 300 trees from the randomForestSRC package in R for the cardiovascular diseases event.
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and predicted risks, is an immense indicator for assessment of the performance of the model. Currently, several 
international guidelines on diabetes management take CVD risk stratification into account and thus a lack of cali-
bration power, either underestimated or overestimated risk of CVD, may result in improper risk-based interven-
tions. An apparent disparity between observed and predicted risks by other existing models developed based on 
predominantly Caucasian population may possibly be attributed to ethnic discrepancy. Several multi-ethnic epi-
demiological studies including the World Health Organization showed that the prevalence of CVD was doubled 
Figure 2. Simplified survival tree on 5-year cardiovascular disease risk.
Figure 3. Kaplan-Meier survival curves of the five final risk groups.
CVD risk group HR (95% CI)
p-value for testing the pairwise difference*
Low Very low Medium High
<5% Reference group
5–9% 1.92 (1.77,2.08) <0.001
10–14% 3.67 (3.40,3.96) <0.001 <0.001
15–19% 4.95 (4.56,5.37) <0.001 <0.001 <0.001
≥20% 8.46 (7.75,9.24) <0.001 <0.001 <0.001 <0.001
Table 2. Hazard ratios for the five final risk groups of cardiovascular diseases. HR = Hazard Ratio; 
CI = Confidence Interval. Notes: *All pairwise comparisons are statistically significant after adjusting for 
multiplicity using Holm’s procedure.
Validation statistics New Model Framingham Swedish model ADVANCE New Zealand model
Harrell’s C statistic 0.677 (0.669,0.685) 0.660 (0.652,0.667) 0.685 (0.677,0.693) 0.665 (0.657,0.673) 0.671 (0.664,0.678)
D statistic 1.054 (1.003,1.112) 0.983 (0.927,1.040) 1.128 (1.079,1.187) 1.104 (1.051,1.153) 1.278 (1.214,1.352)
R2 0.228 (0.207,0.248) 0.182 (0.166,0.199) 0.250 (0.230,0.270) 0.223 (0.205,0.243) 0.225 (0.208,0.246)
Brier score 0.079 (0.077,0.081) 0.080 (0.078,0.082) 0.079 (0.077,0.081) 0.079 (0.077,0.081) 0.080 (0.077,0.082)
Table 3. Performance of new and existing CVD risk models in validation cohort for predicting 5-year risk 
of cardiovascular disease. Notes: The brackets represent 95% confidence interval of corresponding validation 
statistic. *Significant difference in Harrell’s C statistic (P-value < 0.05).
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in Caucasians compared to Chinese10,11, and even the risk of CVD among Asian diabetic population was vastly 
different between Malay, Asian Indian and Chinese15. The reasons for different ethnic CVD risks are thought to be 
due in part to differences in disease profile, genetics and cultural lifestyles10,11,16–18, and thus the prediction model 
for CVD should be ideally be ethnic-specific.
One key feature in our developed model was the inclusion of both eGFR and urine albumin/creatinine ratio 
(ACR) as indicators of the severity of renal impairment. A recent meta-analysis with over 600,000 patients from 
24 cohorts conducted by the Chronic Kidney Disease Prognosis Consortium (CKD-PC) also found that urine 
ACR and eGFR were independent risk factors for CVD, and suggested to incorporate both for CVD risk pre-
diction19. Our analyses also revealed the ranking importance for ACR and eGFR were at the third and fourth 
levels, which were higher than other traditional predictors such as lipid profile. The pathophysiological path-
ways between renal impairment and CVD risk are still not completely understood20. In general, diabetes is one 
of major prognostic factors for the progression of atherosclerosis and accelerated atherosclerosis is observed 
in severe chronic kidney disease resulting in increased risks for CVD20,21. Indeed, there is much concern on 
the enormously detrimental effect of diabetic kidney diseases in CVD risk in the world, particular in Chinese 
populations22. Multinational studies have found that Chinese have higher risks of renal impairment than 
non-Chinese10,11,22–24. Hence, the simultaneous assessment of eGFR and ACR appears to be of key importance in 
deriving CVD risk.
There were several strengths to this study. The dataset used to develop the model was derived from the com-
puterised database of the Hong Kong Hospital Authority (HA), and is representative of the Chinese diabetic 
population managed in primary care setting. The clinical and laboratory data were reliable and accurate as they 
were and extracted systemically directly from the HA’s administrative database.
There were also several limitations. First, our study design was a retrospective one, which may produce biased 
results when compared with a prospective study. Second, other potential predictors such as exercise, diet and 
diabetes education level were not captured in our database and may be worthy of consideration in future studies. 
Third, the data for this study was derived from patients receiving diabetes care in primary care, and the model 
may not be valid in patients being managed in secondary or tertiary care settings. Studies with a longer follow-up 
period, are still needed to estimate the 10-year or longer CVD risk. Further studies to assess its validity and relia-
bility in other settings are needed to examine the performance of the model in other Chinese populations.
Conclusion
Our developed model using tree analysis techniques is able to provide accurate and evidence-based CVD risk 
predictions for Chinese diabetic patients. This can be translated into a decision making tool to help inform 
clinicians regarding intervention choice based on predicted risk rather than relying on a single risk factor. The 
predicted risk stratification can educate, motivate and empower patients to prevent future DM complications. 
At the health policy level, the risk distribution can inform decisions on better service provision and resource 
allocation. For researchers, the prediction models can be used as an indicator to measure the potential ben-
efits of complication prevention in clinical trials on DM interventions in primary care. Further studies are 
needed with a longer follow-up period o to estimate long-term CVD risks and to validate the model in other 
Chinese populations.
Subjects, Materials and Methods
Study Design. This population-based retrospective cohort study included Chinese patients aged between 
18 and 79 years, were clinically diagnosed with T2DM, managed in public primary care clinics and without past 
history of CVD or end stage renal disease. Clinical data were collected and retrieved through the administrative 
database of the HA for patients who had received primary care services from one of the 74 general out-patient 
clinics of the HA between 1 January 2010 and 31 December 2010. The HA is the centralized governmental organ-
isation who governs all public-sector hospitals and primary care clinics, and manages over 50% of DM patients 
under primary care in Hong Kong. Data were made available as part of a territory-wide study on the evalua-
tion of the quality of care of a government-subsidized primary care DM management program25. The clinical 
Figure 4. Calibration plots for observed and predicted 5-year risks of cardiovascular disease.
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diagnosis of T2DM was identified by the International Classification of Primary Care-2 (ICPC-2) code of ‘T90’. 
The presence of CVD including ischaemic heart disease, myocardial infarction, coronary death and sudden death, 
heart failure and fatal and non-fatal stroke was identified by the ICPC-2 of ‘K74’ to ‘K77’ and ‘K89’ to ‘K91’, 
or International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) of 410.x to 414.x, 
428.x, 430.x to 438.x and 798.x. The date of the earliest attendance records was defined as baseline. Each patient 
was followed-up until the date of diagnosis of a CVD event, death or the last follow-up as per the censoring date 
of 30 November 2015, whichever occurred first.
Consent of participants was not necessary as all data were anonymous and were extracted through the com-
puterized administrative system of the Hospital Authority. Ethics approval was received from all the regional 
Institutional Review Boards (IRB) of the Hong Kong Hospital Authority. The reported investigations have been 
carried out in accordance with the principles of the Declaration of Helsinki as revised in 2008.
Potential Classifiers. Potential classifiers consisted of patient’s socio-demographics and clinical characteris-
tics. Socio-demographics included gender, age (<50; 50–64 and ≥65 years old) and smoking status (non-smoker 
and smoker). Clinical characteristics consisted of self-reported duration of T2DM (<2; 2–5 and ≥5 years) and 
presence of diabetic retinopathy. Clinical parameters were categorized based on the local framework for diabetes 
management26. Obesity was defined as body mass index (BMI) ≥27.5 kg/m2 or waist circumference ≥90 cm for 
male; ≥80 cm for female; Unsatisfactory control on haemoglobin A1c (HbA1c) was defined as HbA1c ≥8%; 
Unsatisfactory control on blood pressure (BP) was defined as systolic blood pressure (SBP) ≥140 mmHg or 
diastolic blood pressure (DBP) ≥90 mmHg; Unsatisfactory control on cholesterol was defined based on lipid 
profile (Low-density lipoprotein-cholesterol (LDL-C) ≥3.4 mmol/L, total cholesterol ≥6.2 mmol/L, high-density 
lipoprotein-cholesterol ratio <0.9 mmol/L or triglyceride ≥2.8 mmol/L). Albuminuria included microalbuminu-
ria (urine ACR ≥2.5 mg/mmol & <25 mg/mmol for male or urine ACR ≥3.5 mg/mmol & <35 mg/mmol for 
female) and macroalbuminuria (urine ACR ≥25 mg/mmol for male or urine ACR ≥35 mg/mmol for female). 
The severity of kidney disease was stratified into 3 levels (eGFR ≥90 ml/min/1.73 m2; 60–89 ml/min/1.73 m2 and 
<60 ml/min/1.73 m2). All laboratory assays were performed in accredited laboratories by the College of American 
Pathologists, the Hong Kong Accreditation Service or the National Association of Testing Authorities, Australia.
Data Analysis. The cohort was randomly split on a 2:1 basis, in which two-third of patients were taken as the 
derivation cohort for establishing the classification rule for 5-year CVD risk and the remaining one-third forming the 
validation cohort for validation of the developed rule. Descriptive statistics (percentages for categorical variables, and 
means and standard deviations for continuous variables) of baseline characteristics were displayed for both cohorts.
Based on the deviation cohort, we ranked potential classifiers based on their permutation importance by 
a random survival forest analysis using the randomForestSRC package in R and those classifiers with negative 
importance scores were excluded from further analysis27. Then, we constructed a survival tree model by binary 
recursive partitioning of potential predictors that maximized between-group difference and allowed their inter-
actions, using the party package in R28. The survival tree was constructed in a conditional inference framework, 
which ensured that the right sized tree was developed and required no form of pruning or cross-validation29. 
The HR and average absolute risk of each group, defined by the terminal nodes of the tree, was estimated by Cox 
proportional hazards regression model. For the purpose of fast CVD risk classification in the clinical practice, 
the groups were combined into five risk groups (<5%; 5–9%; 10–14%; 15–19% and ≥20%). The hazard ratio for 
each final risk group was estimated and log-rank test was conducted to compare the incidence of CVD between 
final risk groups.
Using the validation cohort, the performance of the risk classification rule was compared with the ADVANCE, 
Swedish and New Zealand CVD risk scores for T2DM and Framingham CVD risk score for the general popu-
lation12–14,30. Estimated risks from these models were categorized into five risk groups. The Harrell’s C statistic, 
D statistic, R2 statistic and Brier score were calculated for each model to assess the predictive power of each 
model. The Harrell’s C statistic is similar to the area under the curve after taking into account the censoring 
pattern of the patients. A Harrell’s C statistic higher than 0.7 suggests good discrimination of the models31. The 
D statistic is a measure of discrimination where higher value indicates better discrimination. The R2 statistic 
is a measure of explained variation with a higher value indicating better performance. The Brier score is also a 
measure of discrimination where a lower value indicates greater accuracy. The corresponding 95% confidence 
intervals (CIs) were obtained by bootstrapping of size 500. Same analyses were repeated by 10-fold cross valida-
tion. Calibration plots were generated based on the 5 risk groups and observed CVD risks that were obtained by 
5-year Kaplan-Meier estimates in order to evaluate the agreement between predicted and observed CVD risks.
All significance tests were two-tailed and those with p-values less than 0.05 were considered statistically sig-
nificant. The statistical analysis was performed in STATA Version 13.0 and R Version 3.3.1.
Data Availability. The data that support the findings of this study are available from the HA but restrictions 
apply to the availability of these data, which were used under license for the current study, and so are not publicly 
available. Data are however available from the authors upon reasonable request and with permission of the HA.
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